Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
|
|
- Erik Davidson
- 5 years ago
- Views:
Transcription
1 Journal of the American College of Cardiology Vol. 51, No. 21, by the American College of Cardiology Foundation ISSN /08/$34.00 Published by Elsevier Inc. doi: /j.jacc Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention A TRITON TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel Thrombolysis In Myocardial Infarction) Analysis Acute Coronary Syndromes Elliott M. Antman, MD, FACC,* Stephen D. Wiviott, MD,* Sabina A. Murphy, MPH,* Juri Voitk, MD, FACC, Yonathan Hasin, MD, Petr Widimsky, MD, DRSC, Harish Chandna, MBBS, FACC, William Macias, MD, PHD, Carolyn H. McCabe, BS,* Eugene Braunwald, MD, MACC* Boston, Massachusetts; Tallinn, Estonia; Poriya, Israel; Prague, Czech Republic; Victoria, Texas; and Indianapolis, Indiana Objectives Background Methods Results Conclusions We evaluated the relative contributions of the loading and maintenance doses of prasugrel on events in a TRITON TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel Thrombolysis In Myocardial Infarction) analysis. Prasugrel is superior to clopidogrel in preventing ischemic events in patients with an acute coronary syndrome who are undergoing percutaneous coronary intervention, but it is associated with an increased risk of major bleeding. Landmark analyses for efficacy, safety, and net clinical benefit were performed from randomization to day 3 and from day 3 to the end of the trial. Significant reductions in ischemic events, including myocardial infarction, stent thrombosis, and urgent target vessel revascularization, were observed with the use of prasugrel both during the first 3 days and from 3 days to the end of the trial. Thrombolysis In Myocardial Infarction major non coronary artery bypass graft bleeding was similar to clopidogrel during the first 3 days but was significantly greater with the use of prasugrel from 3 days to the end of the study. Net clinical benefit significantly favored prasugrel both early and late in the trial. Both the loading dose and maintenance dose of prasugrel were superior to clopidogrel for the reduction of ischemic events. This result emphasizes the importance of maintaining high levels of inhibition of platelet aggregation via P2Y 12 receptor inhibition, not only for the prevention of periprocedural ischemic events but also during long-term follow-up. The excess major bleeding observed with the use of prasugrel occurred predominantly during the maintenance phase. Approaches to reduce the relative excess of bleeding with prasugrel should focus on the maintenance dose (e.g., reduction in maintenance dose in previously reported high-risk subgroups, such as the elderly and those patients with low body weight). (A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention; NCT ) (J Am Coll Cardiol 2008;51: ) 2008 by the American College of Cardiology Foundation From the *Brigham and Women s Hospital, Boston, Massachusetts; North Estonian Regional Hospital, Tallinn, Estonia; The Kittner and Davidai Institute of Cardiology Center, Poriya, Israel; Cardiocenter, Charles University and University Hospital Vinohrady, Prague, Czech Republic; Detar Hospital, Victoria, Texas; and the Eli Lilly Research Laboratories, Indianapolis. This trial was supported by Daiichi Sankyo Pharma and Eli Lilly and Co. Dr. Macias is an employee of Eli Lilly and Co. Manuscript received January 17, 2008; revised manuscript received March 7, 2008, accepted April 7, The use of dual antiplatelet therapy with aspirin and a thienopyridine is an essential aspect of the supportive pharmacologic regimen administered to patients with an acute coronary syndrome (ACS) who are undergoing percutaneous coronary intervention (PCI) (1 3). To achieve levels of the active metabolite sufficient to inhibit the P2Y 12 receptor around the time of PCI, the thienopyridine dosing strategy begins with a loading dose (1 3) followed by long-term therapy with a daily maintenance dose that should not be discontinued prematurely to avoid ischemic complications (4). Despite its established effectiveness as the thienopyridine element of the dual antiplatelet regimen, clopidogrel has several limitations, including only a modest antiplatelet effect with a delayed onset of action and considerable interpatient variability (5 7). The active
2 JACC Vol. 51, No. 21, 2008 May 27, 2008: Antman et al. Early and Late Benefits of Prasugrel 2029 metabolite is generated more efficiently after the administration of the novel thienopyridine prasugrel, allowing construction of a dosing regimen that consistently yields significantly greater levels of inhibition of platelet aggregation (IPA) after both the loading dose and the maintenance dose (8). The TRITON TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel Thrombolysis In Myocardial Infarction) trial demonstrated that a prasugrel regimen of a loading dose of 60 mg and daily maintenance dose of 10 mg was significantly superior to the standard regimen of clopidogrel (300-mg loading dose and 75-mg daily maintenance dose) in preventing the composite end point of death from cardiovascular causes, nonfatal myocardial infarction (MI), or nonfatal stroke during a median duration of therapy of 15 months (9). The reduction in the primary end point was driven by a significant 24% reduction in MI; significant reductions of 34% and 52% in urgent target vessel revascularization and stent thrombosis, respectively, also occurred (9). These benefits of prasugrel over clopidogrel in preventing ischemic events were achieved at the cost of an increased rate of Thrombolysis In Myocardial Infarction (TIMI) major noncoronary artery bypass grafting (CABG) related bleeding. Net clinical benefit (death from any cause, nonfatal MI, nonfatal stroke, and nonfatal TIMI major non CABG-related bleeding) significantly favored the use of prasugrel over the course of the trial (9). Both the loading and maintenance doses of prasugrel studied in TRITON TIMI 38 yield greater levels of IPA than a standard dose of clopidogrel. Therefore, it is important to assess their relative contributions to the benefits of prasugrel in the reduction of ischemic events and excess bleeding observed in the trial and to examine the effects of prasugrel on the net clinical benefit of these doses. In the present paper, we explored the impact of the loading and maintenance doses of prasugrel over a range of individual pre-specified efficacy end points. The current analysis also provides us the opportunity to assess the timing of prasugrel s impact on the risk of major bleeding and net clinical benefit. Methods Study protocol. As described previously, a total of 13,608 patients with an ACS (both unstable angina/non STsegment myocardial infarction [UA/NSTEMI] and STsegment myocardial infarction [STEMI]) were randomized in TRITON TIMI 38 (9). Because the objective was to compare the use of prasugrel with clopidogrel in patients with ACS who were undergoing PCI, the coronary anatomy of all UA/NSTEMI and post-stemi patients had to be known to be suitable for PCI before randomization (10). If the coronary anatomy was previously known or primary PCI for STEMI was planned, pre-treatment with study drug was allowed for up to 24 h before PCI. Randomization was to occur before the onset of PCI, and blinded study drug administration was to be administered as soon as possible after randomization. Decisions regarding the Abbreviations and Acronyms ACS acute coronary syndrome CABG coronary artery bypass graft HR hazard ratio IPA inhibition of platelet aggregation MI myocardial infarction PCI percutaneous coronary intervention TIMI Thrombolysis In Myocardial Infarction UA/NSTEMI unstable angina/non ST-segment myocardial infarction choice of vessels for PCI, the devices used, and the adjunctive medications were at the discretion of the treating physician. During the maintenance phase, patients were to receive a daily dose of aspirin of 75 to 162 mg and the blinded study drug. After hospital discharge, follow-up visits were conducted at 30-day, 90-day, and at 3-month intervals thereafter for a minimum of 6 months and maximum of 15 months (10). End points. Details of the definitions of the end points are described in previous reports (9,10). In the analyses reported herein, we used the same definitions of MI, urgent target vessel revascularization, stent thrombosis (Academic Research Consortium definite or probable) (11), TIMI major non CABG-associated bleeding, and net clinical benefit as in the main trial. All end points used in the analyses in this report were adjudicated by members of an independent clinical events committee that was blinded to the treatment assignment. The investigators had free and complete access to the data used for these analyses. Members of the TIMI Study Group independently conducted the analyses, wrote the paper using a copy of the raw database for the main trial, and take full responsibility for this report. All analyses were performed with the use of STATA/SE 9.2 (STATA Corp., College Station, Texas). Statistical analyses. All efficacy analyses were performed according to the intention-to-treat principle. Safety analyses were conducted in the cohort of patients who received at least 1 dose of the study drug. The time to first event in the 2 treatment groups was analyzed using Kaplan-Meier curves and compared using the log-rank test. Landmark analyses were performed with the pre-specified windows of randomization to day 3 and from day 3 to the end of the trial (9). The landmark method of survival analysis uses a fixed time after the initiation of treatment to assess the response in treatment groups (12,13). Landmark analysis specifies the cutpoint in time after start of treatment without regard to patient response to therapy. Of importance, this specification provides us the opportunity to perform a separate statistical test to determine whether the response to treatment after the landmark time is different in the treatment groups (12,13). It should be noted that a limitation of landmark analysis is that the original effects of randomization at entry into the trial are no longer present because of deaths or dropouts before the time of the landmark cutpoint. There is a precedent for landmark analyses in both oncology and cardiology (12,13), but because of the observational nature of landmark methodology,
3 2030 Antman et al. JACC Vol. 51, No. 21, 2008 Early and Late Benefits of Prasugrel May 27, 2008: the findings should be interpreted in the context of cumulative survival analyses from randomization to the end of the study (as reported previously for TRITON TIMI 38) (9). The rationale for selection of the day 3 cutpoint for the landmark analyses was to separate, as much as possible, events that could be attributed to the loading dose (periprocedural events) and maintenance dose (events during longterm follow-up) phases of the study. On the basis of a previously reported pharmacodynamic and pharmacokinetic study of prasugrel and clopidogrel, a stable level of IPA attributable to the maintenance dose was evident by day 3 and was also independent of the loading dose of clopidogrel administered (14). When performing the landmark analyses from day 3 to the end of the trial, we ascertained that the number of patients at risk included all patients who were alive, regardless of whether a nonfatal event had occurred during the first 3 days, and had not withdrawn consent for follow-up. We considered p 0.05 to indicate statistical significance. Hazard ratios (HRs) and associated 95% confidence intervals were calculated with a Cox proportional hazards survival model to evaluate the relative treatment effect. For subgroup analyses, an interaction term between the randomized treatment and subgroup was entered into a Cox model. Results A total of 13,608 patients were randomized and formed the intention-to-treat cohort. Of these, 99% underwent PCI and 94% received at least 1 stent. The safety cohort consisted of 13,457 patients who had received at least 1 dose of study drug. Efficacy. The 3-day landmark analyses for the ischemic events of MI, stent thrombosis, and urgent target vessel revascularization are shown in Figure 1. A consistent pattern of significant reductions in each of these end points with prasugrel was found both during the first 3 days and from 3 days to the end of the trial. The reduction in the HR for MI in favor of the prasugrel group was 19% in the first 3 days and 31% from 3 days to the end of the trial. Reductions in the HR were observed with prasugrel for stent thrombosis (51% reduction by 3 days [p 0.006] and 55% reduction from 3 days to the end of the trial [p ]) and urgent target vessel revascularization (34% reduction by 3 days [p 0.047] and 35% reduction from 3 days to the end of the trial [p ]). Of the 300 episodes of urgent target vessel revascularization that occurred from 3 days to the end of the trial, glycoprotein IIb/IIIa inhibitors were used in 57 (19.0%) cases (14 [11.8%] with prasugrel and 43 [23.8%] with clopidogrel; p 0.01). During the maintenance phase, the absolute risk differences with prasugrel were 1.39%, 0.94%, and 1.03% for the end points of MI, stent thrombosis, and urgent target vessel Figure 1 Landmark Analyses of Efficacy Landmark analyses (survival method) of the Kaplan-Meier estimates of myocardial infarction (MI), stent thrombosis, and urgent target vessel revascularization (utvr) during the first 3 days after randomization (left side of each panel) and from 3 days to the end of the study (right side of each panel) are shown for the prasugrel and clopidogrel groups. There were significant reductions in the hazard ratio (HR) for each end point both during the first 3 days and from 3 days to the end of the study that were consistent with independent superiority of the loading and maintenance doses of prasugrel compared with clopidogrel. revascularization, respectively. Inspection of the event curves shows a progressive widening of the differences between the 2 treatment groups for stent thrombosis and urgent target vessel revascularization during the first 3 days and for all 3 efficacy end points from 3 days to the end of the trial. Interaction tests showed no significant effect of stent type at the index PCI (bare-metal stents vs. drug-eluting stents) on the treatment benefits of prasugrel in preventing urgent target vessel revascularization during the first 3 days (P interaction 0.35) or from 3 days to the end of the trial (P interaction 0.17). Similarly, there was no effect of stent type on prevention of stent thrombosis with prasugrel during the first 3 days (P interaction 0.16) or from 3 days to the end of the trial (P interaction 0.64).
4 JACC Vol. 51, No. 21, 2008 May 27, 2008: Antman et al. Early and Late Benefits of Prasugrel 2031 Safety and net clinical benefit. The 3-day landmark analyses for TIMI major non-cabg bleeding and net clinical benefit are shown in Figure 2. Through the first 3 days, the rate of TIMI major non-cabg bleeding was numerically greater with the use of prasugrel (0.74%) compared with clopidogrel (0.61%), but this 0.13% absolute risk increase did not achieve statistical significance. From 3 days to the end of the trial, the rate of major bleeding was significantly greater with the use of prasugrel compared with clopidogrel (39% increase in the HR and 0.48% absolute risk increase). An interaction test of the treatment effect of prasugrel on major bleeding in the 0- to 3-day and 3-day periods was not significant (P interaction 0.62). Inspection of the event curves for major bleeding does not suggest progressive widening of the differences between the treatment groups for the first 3 days, but there does appear to be a steeper increase in the rate of bleeding events over time with prasugrel compared with clopidogrel from 3 days to the end of the study. The net clinical benefit composite end point was significantly in favor of prasugrel both during the first 3 days and from 3 days to the end of the study. The reduction Figure 2 Landmark Analyses of Safety and Net Clinical Benefit Landmark analyses (survival method) of the Kaplan-Meier estimates of Thrombolysis In Myocardial Infarction major noncoronary artery bypass grafting bleeding and net clinical benefit during the first 3 days after randomization (left side of each panel) and from 3 days to the end of the study (right side of each panel) are shown for the prasugrel and clopidogrel groups. There was no significant increase in major bleeding with prasugrel during the first 3 days, but there was a significant increase from 3 days to the end of the study. Net clinical benefit favored prasugrel during both the early and late phases of the study. HR hazard ratio. in the HR was 15% and 13% during the 2 time periods, respectively. Discussion The findings of the present analysis add considerably to the understanding of the profile of the clinical response to prasugrel compared with clopidogrel in patients with an ACS undergoing PCI. We previously reported in a landmark analysis that treatment with prasugrel was associated with significant reductions in the primary end point by the first pre-specified time point, 3 days as well as from 3 days to the end of the trial (9). The exploratory landmark analyses reported here show that there is a consistent significant benefit of prasugrel across multiple individual efficacy end points both early (loading dose phase) and late (maintenance dose phase) after randomization in TRITON TIMI 38. There is internal consistency in that prasugrel prevented a range of ischemic events that are related to platelet activation and aggregation. The benefits of prasugrel in preventing ischemic events not only emerged rapidly (avoidance of periprocedural events) but continued to accrue during long-term treatment (avoidance of recurrent events). These efficacy observations support the concept that prasugrel is superior to the standard dose of clopidogrel as the thienopyridine both for acute pharmacologic support of PCI as well during the chronic phase of management after PCI (9). The chemical structure of prasugrel leads to the more efficient conversion of the prodrug to its active metabolite with less dependence on specific cytochrome P-450 enzymes (8). As reported in studies of platelet function, there is a very rapid onset of substantial levels of IPA achievable with prasugrel, levels that are significantly greater than can be achieved by standard dosing with clopidogrel (8). The greater prevention of the periprocedural events of MI, stent thrombosis, and urgent target vessel revascularization during the first 3 days with prasugrel compared with standard dosing with clopidogrel is therefore likely the result of rapid attainment of much greater levels of IPA. The speed of onset of prasugrel s antiplatelet effect offers the clinician the opportunity to determine that the coronary anatomy is suitable for PCI before committing to irreversible P2Y 12 inhibition. This strategy overcomes the liability of a commonly used strategy of pre-treating with clopidogrel before PCI, which exposes patients to substantially increased risks of perioperative bleeding if urgent CABG surgery is required as well as non CABG-related bleeding (15 17). The 10-mg maintenance dose of prasugrel also produces significantly greater levels of IPA than the standard 75-mg maintenance dose of clopidogrel (8). Our landmark analyses and the shape of the event curves from day 3 through the end of the trial are consistent with an independent benefit of prolonged treatment with prasugrel compared with clopidogrel. The more consistent and greater levels of IPA with 10 mg of prasugrel reported in platelet function studies
5 2032 Antman et al. JACC Vol. 51, No. 21, 2008 Early and Late Benefits of Prasugrel May 27, 2008: translated into prevention of more ischemic events in patients during the maintenance phase of therapy after PCI (8). Especially notable among these results was the large treatment effect on stent thrombosis, an infrequent but serious and often fatal complication after PCI (18). The landmark analyses reported herein provide one important step in linking the greater levels of IPA achieved with the loading and maintenance doses of prasugrel compared with standard doses of clopidogrel in preventing early and late ischemic events. Of note, significantly greater levels of IPA were achieved with the loading and maintenance doses of prasugrel studied in the TRITON TIMI 38 trial even when compared with higher-than-standard doses of clopidogrel (600-mg loading dose and 150-mg maintenance dose) in the PRINCIPLE TIMI 44 (Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation Thrombolysis In Myocardial Infarction) trial (19). Furthermore, the ISAR-REACT 2 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment) investigators reported that even pre-treatment with 600 mg of clopidogrel before PCI was inadequate antiplatelet therapy in patients with NSTEMI and additional treatment with abciximab was required to limit ischemic events (20). Although formal interaction testing of the impact of prasugrel on early and late bleeding events was not significant, it should be noted that such interaction tests are relatively weak and may fail to detect important quantitative differences if the number of events is small, as is the case for bleeding within the first 3 days. On the basis of the absolute and relative event rates, our landmark analysis suggests the period from 3 days to the end of the trial as the major risk period for excess bleeding with prasugrel. As noted in several Food and Drug Administration guidance documents, the relationship between exposure and response to a drug may place certain subsets of the population at increased risk of toxicity (21,22). This relationship can be assessed through population-pharmacokinetic studies embedded within a large trial (21). Modeling can be used to predict modified dosing regimens for special populations to maintain efficacy and reduce risk (21). We previously identified several high-risk patient subsets of the TRITON TIMI 38 trial population for whom net clinical benefit analyses were neutral (i.e., reduction in primary end point events was offset by an increase in bleeding events) and who may be candidates for a reduced maintenance dose (9). These subsets include individuals 75 years of age and those weighing 60 kg (together representing approximately 16% of the patients studied in TRITON TIMI 38). Although the elderly and low body weight patients tended to have fewer primary end point events with prasugrel versus clopidogrel, this result was offset by a greater rate of major bleeding, resulting in a neutral net clinical benefit end point (9). Our landmark analyses of major bleeding suggest that the focus of ongoing population-pharmacokinetic analyses in TRITON TIMI 38 should be on modeling to identify a suitable reduction of the maintenance dose in such high-risk groups. Clinical implications. The superiority of both the loading dose and maintenance dose of prasugrel compared with the standard dose of clopidogrel emphasizes the benefits of high levels of IPA via P2Y 12 receptor inhibition not only for prevention of periprocedural ischemic events but also during long-term follow-up. The greatest risk of the more aggressive antiplatelet regimen with prasugrel is excess major bleeding, especially during chronic therapy. Efforts to minimize the risk of excess bleeding with prasugrel are needed. A logical approach in this regard is reduction of the maintenance dose (e.g., 5 mg) in previously reported highrisk subgroups (elderly, low body weight) (9). Reprint requests and correspondence: Dr. Elliott M. Antman, Cardiovascular Division, Brigham and Women s Hospital, TIMI Study Group, 350 Longwood Avenue, 1st Floor, Boston, Massachusetts eantman@rics.bwh.harvard.edu. REFERENCES 1. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction). J Am Coll Cardiol 2007;50:e Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol 2004;44:e King SB III, Smith SC Jr., Hirshfeld JW Jr., Jacobs AK, Morrison DA, Williams DO focused update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (2007 Writing Group to Review New Evidence and Update the 2007 ACC/AHA/SCAI Guideline Update for Percutaneous Coronary Intervention). J Am Coll Cardiol 2008;51: Grines CL, Bonow RO, Casey DE Jr., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 2007;49: Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol 2003;91: Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45: Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288: Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007;25: Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357: Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes:
6 JACC Vol. 51, No. 21, 2008 May 27, 2008: Antman et al. Early and Late Benefits of Prasugrel 2033 design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 2006;152: Mauri L, Hsieh WH, Massaro JM, Ho KK, D Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356: Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983;1: Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297: Payne CD, Li YG, Small DS, et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007;50: Leong JY, Baker RA, Shah PJ, Cherian VK, Knight JL. Clopidogrel and bleeding after coronary artery bypass graft surgery. Ann Thorac Surg 2005;80: Yende S, Wunderink RG. Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit Care Med 2001;29: Szuk T, Gyongyosi M, Homorodi N, et al. Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort. Am Heart J 2007;153: Windecker S, Meier B. Late coronary stent thrombosis. Circulation 2007;116: Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention. The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation Thrombolysis in Myocardial Infarction 44 Trial. Circulation 2007;116: Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006;295: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry. Population Pharmacokinetics, Available at: Accessed December 21, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry. Exposure-Response Relationships Study Design, Data Analysis, and Regulatory Applications, Available at: Accessed December 21, 2007.
Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationתרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון מרכז רפואי רבין
תרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון בי""י מרכז רפואי רבין 1. Why should clopidogrel be replaced? 2. Prasugrel 3. Ticagrelor 4. Conclusions CURE TRIAL ACS pts 20 % reduction
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More informationPRASUGREL HYDROCHLORIDE (Effient Eli Lilly Canada Inc.) Indication: Acute Coronary Syndrome
CEDAC FINAL RECOMMENDATION PRASUGREL HYDROCHLORIDE (Effient Eli Lilly Canada Inc.) Indication: Acute Coronary Syndrome Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that
More informationHeart disease is the leading cause of death
ACS AND ANTIPLATELET MANAGEMENT: UPDATED GUIDELINES AND CURRENT TRIALS Christopher P. Cannon, MD,* ABSTRACT Acute coronary syndrome (ACS) is an important cause of morbidity and mortality in the US population
More informationJournal of the American College of Cardiology Vol. 54, No. 25, by the American College of Cardiology Foundation ISSN /09/$36.
Journal of the American College of Cardiology Vol. 54, No. 25, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.10.005
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationClopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More informationPrasugrel: Son of Clopidogrel or Distant Cousin? Disclosures. Objectives
Prasugrel: Son of Clopidogrel or Distant Cousin? By John J. Bon, Pharm.D., BCPS Lead Clinical Pharmacist, Critical Care Summa Health System Disclosures I have no actual or potential conflict of interest
More informationUpdated and Guideline Based Treatment of Patients with STEMI
Updated and Guideline Based Treatment of Patients with STEMI Eli I. Lev, MD Director, Cardiac Catheterization Laboratory Hasharon Hospital, Rabin Medical Center Associate Professor of Cardiology Tel-Aviv
More informationP2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationOptimal Duration and Dose of Antiplatelet Therapy after PCI
Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI
More information1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES
1 Comparison of Ischemic and Bleeding Events After Drug- Eluting Stents or Bare Metal Stents in Subjects Receiving Dual Antiplatelet Therapy: Results from the Randomized Dual Antiplatelet Therapy (DAPT)
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationRivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction
Journal of the American College of Cardiology Vol. 61, No. 18, 2013 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.01.066
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationOral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine
Oral Antiplatelet Therapy in PCI/ACS Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Basic Concepts Thrombus Formation Two key elements:
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationMore than 1 million percutaneous coronary intervention
n report n Percutaneous Coronary Intervention: Assessing Coronary Vascular Risk Associated With Bare-Metal and Drug-Eluting Stents Sarah A. Spinler, PharmD, FCCP, BCPS (AQ Cardiology) Abstract Percutaneous
More information'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome'
'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome' Miguel Sousa Uva Chair ESC Cardiovascular Surgery WG Hospital da Cruz Vermelha Portuguesa
More informationPrasugrel a step ahead in antiplatelet therapy
Prasugrel a step ahead in antiplatelet therapy VS Srinath, MD (Med), DNB (Cardiology) The burden of atherosclerotic disease in the United States and across the world is vast. Although the symptoms of atherosclerosis
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationHead-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
Date: August 21, 2008 Refer to: Carole Copeland (OUS) Eli Lilly and Company 317-277-3661 (office) 317-610-6196 (cell) Tammy Hull (U.S.A.) Eli Lilly and Company 317-651-9116 (office) 317-614-5132 (cell)
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationClopidogrel vs New Antiplatelet Therapy (Prasugrel) Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany
Clopidogrel vs New Antiplatelet Therapy () Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany Seoul, April 3, 21 Dual Antiplatelet Therapy for Stenting MACE, % 12 1 8 6 In
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationCardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.
Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. ST Elevation Myocardial Infarction (STEMI)-Acute Coronary Syndrome Guidelines:
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationReview Article Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes
Review Article Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes Tirtha Patel V *, Jigna Shah S and Patel CN Department of Clinical Pharmacy, Shri Sarvajanik Pharmacy College, Mehsana, Gujarat,
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 9, 2013 Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville
More informationWhy and How Should We Switch Clopidogrel to Prasugrel?
Case Presentation Why and How Should We Switch Clopidogrel to Prasugrel? Shaul Atar Western Galilee Medical Center Nahariya, ISRAEL Case Description A 67 Y. Old Pt. admitted to IM with anginal CP. DM,
More informationSession Objectives. Clopidogrel Resistance. Clopidogrel (Plavix )
Session Objectives New Antithrombotics and Real Time Genetic Testing: Their Role in the Vascular Patient Margaret C. Fang, MD, MPH Associate Professor of Medicine Division of Hospital Medicine Medical
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationNew insights in stent thrombosis: Platelet function monitoring. Franz-Josef Neumann Herz-Zentrum Bad Krozingen
New insights in stent thrombosis: Platelet function monitoring Franz-Josef Neumann Herz-Zentrum Bad Krozingen New insights in stent thrombosis: Platelet function monitoring Variability of residual platelet
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationIs Cangrelor hype or hope in STEMI primary PCI?
Is Cangrelor hype or hope in STEMI primary PCI? ARUN KALYANASUNDARAM MD, MPH, FSCAI HOPE Issues with platelet inhibition in STEMI Delayed onset In acute settings, achieving the expected antiplatelet effect
More informationArticles. Funding TRITON TIMI 38 was supported by research grants from Daiichi Sankyo and Eli Lilly.
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in
More informationNew antiplatelets in NSTEMI. Overview: dual anti-platelet oral therapy
Cairo, Egypt 2010 New antiplatelets in NSTEMI Steen D. Kristensen, FESC Department of Cardiology Aarhus University Hospital Skejby Denmark Overview: dual anti-platelet oral therapy Aspirin Clopidogrel
More information2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with American Association for Thoracic Surgery, American
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationEffect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI Dr Sasha Koul, MD Dept of Cardiology, Lund University Hospital, Lund, Sweden
More informationTechnology appraisal guidance Published: 23 July 2014 nice.org.uk/guidance/ta317
Prasugrel with percutaneous coronary intervention ention for treating acute coronary syndromes Technology appraisal guidance Published: 23 July 2014 nice.org.uk/guidance/ta317 NICE 2018. All rights reserved.
More informationINDIVIDUALIZED MEDICINE
CENTER FOR INDIVIDUALIZED MEDICINE Clopidogrel Pharmacogenetics Can We Impact Clinical Practice? Michael E. Farkouh, MD, MSc Peter Munk Cardiac Centre University of Toronto Naveen Pereira MD Mayo Clinic
More informationST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department
ST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department decision-making. They have become the cornerstone of many ED protocols for
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationClopidogrel Response Variability and Platelet Function Testing: Should Routine Practice Be Changed in Interventional Cardiology?
Clopidogrel Response Variability and Platelet Function Testing: Should Routine Practice Be Changed in Interventional Cardiology? Matthew J. Price MD, FACC Director, Cardiac Catheterization Laboratory Scripps
More informationHow Long Patietns Will Be on Dual Antiplatelet Therapy?
How Long Patietns Will Be on Dual Antiplatelet Therapy? Ron Waksman,, MD, FACC Professor of Medicine (Cardiology) Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center
More informationMortality Benefit With Prasugrel in the TRITON TIMI 38 Coronary Artery Bypass Grafting Cohort
Journal of the American College of Cardiology Vol. 60, No. 5, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.03.030
More informationAnti-platelet therapies and dual inhibition in practice
Anti-platelet therapies and dual inhibition in practice Therapeutics; Sept. 25 th 2007 Craig Williams, Pharm.D. Associate Professor of Pharmacy Objectives 1. Understand the pharmacology of thienopyridine
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationJournal of the American College of Cardiology Vol. 50, No. 19, by the American College of Cardiology Foundation ISSN /07/$32.
Journal of the American College of Cardiology Vol. 50, No. 19, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.07.053
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST How to manage antiplatelet treatment in patients with diabetes in acute coronary syndrome Lars Wallentin Professor of Cardiology, Chief Researcher Cardiovascular Science
More informationDual Antiplatelet duration in ACS: too long or too short?
Dual Antiplatelet duration in ACS: too long or too short? Leonardo Bolognese, MD, FESC, FACC Cardiovascular Department, Arezzo, Italy Paradigm Shift the ideal duration of DAPT: a moving target Early (stent-related)
More informationFacilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients?
Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction Is it beneficial to patients? Seung-Jea Tahk, MD. PhD. Suwon, Korea Facilitated PCI.. background Degree of coronary flow at
More informationA Randomized Comparison of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin After the Placement of Coronary Artery Stents
Journal of the American College of Cardiology Vol. 41, No. 6, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02974-1
More informationTiming of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC
Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke Clinical
More informationOriginal Article Impact of timing to coronary angiography in acute coronary syndrome on contemporary clinical practice
Am J Cardiovasc Dis 2012;2(3):248-252 www.ajcd.us /ISSN:2160-200X/AJCD1204002 Original Article Impact of timing to coronary angiography in acute coronary syndrome on contemporary clinical practice Angela
More informationOtamixaban for non-st-segment elevation acute coronary syndrome
Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationNine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large coronary vessel lesions
Journal of Geriatric Cardiology (2017) 14: 35 41 2017 JGC All rights reserved; www.jgc301.com Research Article Open Access Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large
More informationManagement of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?
Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013
More informationGRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017
GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY Nick Collins February 2017 DISCLOSURES Before I commence Acknowledge.. Interventional Cardiologist Perception evolved. Interventional
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationQuale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor
Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor Leonardo Bolognese Cardiovascular Department, Arezzo, Italy Platelet Reactivity in Patients with STEMI Undergoing Primary PCI Campo G et
More informationUpcoming Evidence and Practice of Optimal Antiplatelet Therapy in DES Era?
Upcoming Evidence and Practice of ptimal Antiplatelet Therapy in DES Era? Polymorphism in Metabolism of Clopidogrel and Its Clinical Implications and Management Alexandra Lansky MD Columbia University
More informationCytochrome P450 interactions
Cytochrome P450 interactions Learning objectives After completing this activity, pharmacists should be able to: Explain the mechanism of action of clopidogrel-ppi interaction Assess the risks and benefits
More informationThe Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI
The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI Interventional Cardiologist Cardiovascular Institute of the South Director of Cardiovascular Services St. Charles Parish
More informationCLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA
RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA Dr Lincoff is an interventional cardiologist and the Vice Chairman for Research
More informationBy Joseph L. Fredi, M.D., FACC, and Carol R. Scott, B.S.N., M.S.N., Medical Directors, STEMI Network Vanderbilt Heart and Vascular Institute
STEMI Network STEMI News By Joseph L. Fredi, M.D., FACC, and Carol R. Scott, B.S.N., M.S.N., Medical Directors, STEMI Network Vanderbilt Heart and Vascular Institute Joseph L. Fredi, M.D., FACC Unless
More informationΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ. Εξατοµικευµένη αντιαιµοπεταλιακή αγωγή. Ποιο είναι το µέλλον?
ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ ΕΡΕΥΝΗΤΙΚΟ ΚΕΝΤΡΟ ΑΘΗΡΟΘΡΟΜΒΩΣΗΣ Εξατοµικευµένη αντιαιµοπεταλιακή αγωγή. Ποιο είναι το µέλλον? Αλέξανδρος Δ. Τσελέπης, MD, PhD Καθηγητής Βιοχηµείας - Κλινικής Χηµείας Disclosures
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationDaiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
More informationAntiplatelet therapy is the mainstay of pharmacological
Contemporary Reviews in Interventional Cardiology Pretreatment With Antiplatelet Drugs in Invasively Managed Patients With Coronary Artery Disease in the Contemporary Era Review of the Evidence and Practice
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters
Reduction in Recurrent Cardiovascular Events with Prasugrel Compared with Clopidogrel in Patients with Acute Coronary Syndromes from the TRITON-TIMI 38 Trial The Harvard community has made this article
More informationAntiplatelet Therapy: how, why, when? For Coronary Stenting
Antiplatelet Therapy: how, why, when? For Coronary Stenting Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University of Florida
More informationTim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute
Tim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute Implications of Pre-loading on Patients Undergoing Coronary Angiography Angiography Define
More informationDisclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.
Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,
More informationACUTE CORONARY SYNDROME
A supplement to MONTHLY PRESCRIBING REFERENCE April 2014 Issue #18 Intervention & Prevention: Keeping Current with ACUTE CORONARY SYNDROME JOURNAL CLUB Pretreatment with prasugrel in non-st-segment elevation
More informationHorizon Scanning Centre November 2012
Horizon Scanning Centre November 2012 Cangrelor to reduce platelet aggregation and thrombosis in patients undergoing percutaneous coronary intervention99 SUMMARY NIHR HSC ID: 2424 This briefing is based
More informationCase Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA
Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA Case History A 50-year-old man with type 1 diabetes mellitus and hypertension presents after experiencing 1 hour of midsternal chest pain that began after
More informationReduction in Stent Thrombosis better tablets or better stents?
Reduction in Stent Thrombosis better tablets or better stents? Dr James Cotton MD FRCP Heart and Lung Centre Wolverhampton MY CONFLICTS OF INTEREST ARE Speaker Fees/Honoraria/Travel Support Lilly/Daiichi
More informationCOAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY
COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY VALTER CASATI, M.D. DIVISION OF CARDIOVASCULAR ANESTHESIA AND INTENSIVE CARE CLINICA S. GAUDENZIO NOVARA (ITALY) ANTIPLATELET
More informationDirect Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI
Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI Charles A. Simonton MD, FACC, FSCAI Sanger Clinic Medical Director Clinical Innovation and Research Carolinas Heart
More informationJournal of the American College of Cardiology Vol. 49, No. 23, by the American College of Cardiology Foundation ISSN /07/$32.
Journal of the American College of Cardiology Vol. 49, No. 23, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.01.093
More informationDiabetic Patients: Current Evidence of Revascularization
Diabetic Patients: Current Evidence of Revascularization Alexandra J. Lansky, MD Yale University School of Medicine University College of London The Problem with Diabetic Patients Endothelial dysfunction
More informationAngioplastica coronarica nel paziente anziano ad alto rischio emorragico
Attualità in Cardiologia Aprilia, Enea Hotel 22 ottobre 2011 Angioplastica coronarica nel paziente anziano ad alto rischio emorragico Fabrizio Tomai, MD, FACC, FESC Dept. of Cardiovascular Sciences - Interventional
More informationOral Antiplatelet Therapy in Patients with ACS: A Focus on Prasugrel and Ticagrelor
Oral Antiplatelet Therapy in Patients with ACS: A Focus on Prasugrel and Ticagrelor Nicolas W. Shammas, MS, MD, FACC Coronary and Peripheral Interventionalist Cardiovascular Medicine, PC Research Director,
More informationTCT mdbuyline.com Clinical Trial Results Summary
TCT 2012 Clinical Trial Results Summary FAME2 Trial: FFR (fractional flow reserve) guided PCI in all target lesions Patients with significant ischemia, randomized 1:1 Control arm: not hemodynamically significant
More informationDavid E. Kandzari, MD Director, Interventional Cardiology Research Scripps Clinic La Jolla, California
38 RCTs 18,000 pts Identifying the Optimal Duration of DAPT Less is More, More or Less David E. Kandzari, MD Director, Interventional Cardiology Research Scripps Clinic La Jolla, California kandzari.david@scrippshealth.org
More information